Anika Therapeutics (NASDAQ:ANIK) Issues Earnings Results

Anika Therapeutics (NASDAQ:ANIK) announced its earnings results on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13), Zacks reports. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Anika Therapeutics Trading Up 1.9 %

Shares of Anika Therapeutics stock traded up $0.32 on Wednesday, hitting $17.11. 113,756 shares of the company traded hands, compared to its average volume of 68,231. Anika Therapeutics has a 52 week low of $15.40 and a 52 week high of $29.11. The company has a market cap of $250.59 million, a PE ratio of -2.57 and a beta of 0.95. The stock’s 50 day moving average price is $16.91 and its 200-day moving average price is $19.66.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.